| AZ | EN | RU

STATISTICS


FIRST-LINE THERAPY PRESCRIPTIONS IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
Babayeva G.H., Mahmudov U.R., Mammadov E.E., Guliyev F.V., Verdiyev E.Kh., Machanov U.R., Ibishev R.F., Huseynov H.M., Zalov Z.S., Ismayilova S.Y., Hasanov R.A., Ibrahimli H.I., Cano-Català A., Parra P.P., Moreira L., Nyssen O.P., Mégraud F., O'Morain C., Gisbert J.P.

DOI: 10.61775/2413-3302.v1i35.09

SUMMARY
Background. Gastric lesions associated with Helicobacter pylori, eradication issues in terms of the choice of antibiotics and duration of therapy continue to remain one of the most pressing topics in modern healthcare. Methods. Data were collected from the European Registry on Helicobacter pylori Management (Hp-EuReg) and quality reviewed from January 2020 to May 2023 at AEG-REDCap. All treatment-naïve cases were assessed for choice of regimens and duration, as well as dosing of proton pump inhibitor therapy. Results. The study included 3,898 patients (67% reported dyspepsia). Triple regimens were most often prescribed (82%), the PPI-clarithromycin-amoxicillin scheme being used in 54% of patients. Duration of treatment was of 14 days (56%), 10 days (27%) and 7 days (17%). Conclusion. The prescribed H. pylori eradication regimens during the period 2020–2023 in Azerbaijan adhered partially to the Maastricht recommendations.
Keywords: Hp-EuReg, Helicobacter pylori, antisecretory therapy, first-line treatment, bismuth, eradication rate

REFERENCES
  1. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V Florence Consensus Report // Gut 2017;66:6-30. doi:10.1136/gutjnl-2016-312288.
  2. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J-M, Schulz Ch, Gasbarrini A, et al. Management of Helicobacter pylori infection: the Maastricht VI Florence consensus report // Gut 2022;0:1-39. doi:10.1136/gutjnl-2022-327745.
  3. Miyaki A, Yamaguchi K, Ida A, Miyauchi T. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility // Minerva Gastroenterologica e Dietologica 2016 September;62(3):234-9.
  4. Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review // World J Methodol. 2015; (5): 164-74.
  5. Maev I.V., Andreev D.N. Molecular genetic predictors of resistance to Helicobacter pylori therapy // Therapeutic archive. 2017; 89 (8): 5-12.
  6. Simanenkov V.I., Zakharova N.V., Zhebrun A.B., Svarval A.V., Savilova I.V., Ferman R.S. Resistance of Helicobacter pylori to antimicrobial drugs according to the results of bacteriological testing // Therapist. 2015; (4):10
  7. McNicholl AG, O’Morain CA, Megraud F, et al. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg) // Helicobacter 2019; (24): 5: https://doi.org/10.1111/hel.12630
  8. Lerardi E., Losurdo G., La Fortezza R.F., Principi M., Barone M., Di Leo A. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness // World J Gastroenterol. 2019; 25(34): 5097-5104.
  9. Gao W., Zhang X., Yin Y., Yu S., Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis // Int J Immunopathol Pharmacol. 2021; 35: doi: 10.1177/20587384211030397
  10. Rojsanga W, Chanpiwat K, Bunchorntavakul C. 7-day High-dose Proton Pump Inhibitor Versus 10-day Standard Concomitant Therapy for Helicobacter pylori Eradication in Thai Patients: A Randomized Controlled Trial // J Med Assoc Thai 2019; 102 (12):12.